SCHEMBL31347134

SCHEMBL31347134

OCc1cc(Cl)nc2c1ccn2-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 2/20 0.35
▸ FGFR1 P11362 1/20 0.35
▸ KDM4E B2RXH2 4/20 0.34
▸ POLB P06746 1/20 0.34
▸ CTDSP1 Q9GZU7 1/20 0.34
▸ EGLN1 Q9GZT9 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ MAPT P10636 2/20 0.33
▸ USP2 O75604 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ COMT P21964 1/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26107594 1.00 SRC (0.35) SRCFGFR1KDM4EPOLBCTDSP1
SCHEMBL24528688 0.80 ALDH1A1 (0.39) SRCFGFR1KDM4EPOLBCTDSP1
SCHEMBL30611999 0.79 IRAK4 (0.35) FGFR1HPGDSMN1; SMN2GAAMAPK8
SCHEMBL26103862 0.79 IRAK4 (0.35) FGFR1HPGDSMN1; SMN2GAAMAPK8
SCHEMBL26109399 0.79 HRH4 (0.42) SRCKDM4EPOLBEGLN1ALDH1A1
SCHEMBL26105306 0.76 NOTUM (0.32) KDM4EALDH1A1
SCHEMBL30612138 0.76 NOTUM (0.32) KDM4EALDH1A1
SCHEMBL3972718 0.74 KDM4E (0.50) KDM4EPOLBALDH1A1MAPTUSP2
SCHEMBL30612046 0.74 ATM (0.38) SRCFGFR1KDM4EPOLBCTDSP1
SCHEMBL26102261 0.74 ATM (0.38) SRCFGFR1KDM4EPOLBCTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-07-03 — — US disclosed
CN-119585252-A Bicyclic heteroaryl containing compounds as IKZF2 degrading agents 翁科皮亚治疗公司和SK生命科学实验室 2025-03-07 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS IKZF1, IKZF2, IKZF3 SRC 2092/4885FGFR1 1763/4885KDM4E 647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback